Intestinal Growth in Parenterally-Fed Rats Induced by the Combined Effects of Glucagon-like Peptide 2 and Epidermal Growth Factor

Abstract

Background: Parenteral nutrition and the absence of luminal feeding result in impaired intestinal growth and differentiation of enterocytes. Glucagon-like peptide 2 (GLP-2) and epidermal growth factor (EGF) have each been shown to have trophic effects on the intestine, and thus have the potential to benefit patients fed parenterally, such as those with intestinal failure from short bowel syndrome. We report studies aimed to determine whether there may be synergistic effects of these 2 peptides. Methods: Rats were established on parenteral nutrition (PN) and infused for 6 days with GLP-2 (20 μg/d), EGF (20 μg/d), or GLP-2 + EGF (20 μg/d of each). These groups were compared with untreated PN-fed and orally-fed controls. Tissue was obtained from small intestine and colon to determine growth, proliferation, and representative gene expression. Results: Small intestinal weight was increased by 75%, 43%, and 116% in the GLP-2, EGF, and GLP-2 + EGF groups, respectively, compared with PN controls (all p < .001). Cell proliferation increased with GLP-2, EGF, and GLP-2 + EGF in proximal small intestine by factors of 2.3, 1.7, and 3.4 respectively (p < .001). A synergistic effect on villous and crypt area was observed in the proximal small intestine when GLP-2 and EGF were combined (p < .05). GLP-2 had no effect in the colon, unlike EGF. Further studies showed GLP-2 + EGF significantly increased expression in distal small intestine of transcripts for the bile acid transport protein IBABP (p < .05) and showed a significant correlation between the expression of IBABP and the transcription factor HNF-4. Conclusions: Both GLP-2 and EGF upregulate growth of the small intestine, and this is augmented when GLP-2 and EGF are combined. These findings may lead to improved treatment of patients receiving PN.

In parenterally fed rats, both GLP-2 and EGF are able to stimulate small intestinal growth and differentiation, and the combined effects are greater than with either GLP-2 or EGF alone.

Get full access to this article

View all access options for this article.

References

Nightingale J, ed. Intestinal Failure. London: Greenwich Medical Media; 2001.

Wright NA, Goodlad RA. Cytokines and growth factors in gastroenterology. Ballieres Clin Gastroenterol. 1996 ;10:1 .

Goodlad RA, Wilson TJ, Lenton W, Gregory H, McCullagh KG, Wright NA. Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats. Gut. 1987 ;28:573– 582.

Sullivan PB, Brueton MJ, Tabara Z, Goodlad RA, Lee CY, Wright NA. Epidermal growth factor in necrotising enteritis. Lancet. 1991 ;338:53– 54.

Walker-Smith JA, Phillips AD, Walford N, et al. Intravenous epidermal growth factor/urogastrone increases small-intestinal cell proliferation in congenital microvillous atrophy. Lancet. 1985 ;2:1239– 1240.

Berlanga-Acosta J, Playford RJ, Mandir N, Goodlad RA. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut. 2001 ;48:803– 807.

Heitz P, Kasper M, Van Norden S, Polak JM, Gregory H, Pearse AGE. Immunohistochemistry localisation of urogastrone to human duodenal and submaxillary glands. Gut. 1978 ;19:408– 413.

Playford RJ, Hanby AM, Gschmeissner S, Peiffer LP, Wright NA, McGarrity T. The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. Gut. 1996 ;39:262– 266.

Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002 ;122:531– 544.

10.

Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene.Nature. 1983;304:368– 371.

11.

Mojsov S, Henrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem. 1986 ;261:11880– 11889.

12.

Orskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 1987 ;47:165– 174.

13.

Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.Endocrinology. 1986;119:1467– 1475.

14.

Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Molec Endo. 1996;10:342– 355.

15.

Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 1999 ;96:1569– 1573.

16.

Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents.Gastroenterology. 2000;119:744– 755.

17.

Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA. 2001 ;98:12497– 12502.

18.

Walsh NA, Yusta B, Dacambra MP, Anini Y, Drucker DJ, Brubaker PL. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa.Endocrinology. 2003;144:4385– 4392.

19.

Swietlicki E, Iordanov H, Fritsch C, Yi L, Levin MS, Rubin DC. Growth factor regulation of PC4/TIS7, an immediate early gene expressed during gut adaptation after resection. JPEN J Parenter Enteral Nutr. 2003 ;27:123– 131.

20.

Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001 ;120:806– 815.

21.

Drucker DJ, Ehrlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93:7911– 7916.

22.

Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol. 1997 ;273:G559– G563.

23.

Kitchen PA, Fitzgerald AJ, Goodlad RA, et al. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression. Am J Physiol. 2000 ;278:G425– G428.

24.

Ghatei MA, Goodlad RA, Taheri S, et al. Proglucagon-derived peptides in intestinal epithelial proliferation— glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig Dis Sci. 2001;46:1255– 1263.

25.

Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome.Am J Physiol Gastrointest Liver Physiol. 2004 ;286:G964– G972.

26.

Drucker DJ, Deforest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly(2)]glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol. 1997 ;36:G1252– G1262.

27.

Howard A, Goodlad RA, Walters JR, Ford D, Hirst BH. Increased expression of specific intestinal amino acid and peptide transporter mRNA in rats fed by PN is reversed by GLP-2. J Nutr. 2004 ;134:2957– 2964.

28.

Barley NF, Taylor V, Shaw-Smith CJ, et al. Human ileal bile acid-binding protein promoter and the effects of CDX2. Biochim Biophys Acta. 2003;1630:138– 143.

29.

Playford RJ, Marchbank T, Mandir N, et al. Effects of keratinocyte growth factor (KGF) on gut growth and repair. J Pathol. 1998 ;184:316– 322.

30.

Barley NF, Prathalingam SR, Zhi P, Legon S, Howard A, Walters JRF. Factors involved in the duodenal expression of the human calbindin-D9k gene.Biochem J. 1999;341:491– 500.

31.

Barley NF, Chakravarty P, Sitrin MD, et al. Gene expression in transposed segments of rat small intestine. Gastroenterology. 1997 ;112:A860 .

32.

Playford RJ, Wassan H, Ghosh S. Effects of growth factors and receptor blockade on gastrointestinal cancer. Gut. 2004 ;53:1059– 1063.

33.

Goodlad RA, Mandir N, Meeran K, Ghatei MA, Bloom SR, Playford RJ. Does the response of the intestinal epithelium to keratinocyte growth factor vary according to the method of administration? Regul Pept. 2000 ;87:83– 90.

34.

Bashir O, Fitzgerald AJ, Berlanga-Acosta J, Playford RJ, Goodlad RA. Effect of EGF administration on intestinal cell proliferation, crypt fission and polyp formation in Min mice. Clin Sci. 2003 ;105:323– 330.

35.

Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.Gut. 2004;53:1145– 1150.